ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Interchangeability of CSF and PET to identify Alzheimer's disease pathology.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionEstablishing interchangeability between cerebrospinal fluid (CSF) and positron emission tomography (PET) for patient identification may improve access to Alzheimer's disease (AD) therapies.
methodsAlzheimer's Disease Neuroimaging Initiative participants with mild cognitive impairment or AD dementia and available CSF, florbetapir PET, and/or flortaucipir PET were included. The interchangeability of CSF (per label threshold/method) and PET was evaluated for patient identification.
resultsFujirebio Lumipulse amyloid beta (Aβ) 42/Aβ40 ( DISCUSSION: CSF assays were interchangeable with amyloid PET to identify patients with AD pathology and were in high agreement with elevated early temporal flortaucipir PET. CSF biomarkers may be used as a robust alternative to PET, potentially increasing access to AD diagnosis and disease-modifying treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.